Active, not recruiting

3

109

US, Canada, Europe

TMC435, Pegylated interferon alpha-2a, Ribavirin

Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals

Hepatitis C Virus Genotype-1

08/13

08/13

Completed

2/3

200

RoW

Sofosbuvir +daclatasvir+ simeprevir+Ribavirin

Benha University

Male Infertility, HCV

11/22

12/22

Recruiting

1b/2

64

RoW

HTMC0435, Temozolomide

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Recurrent Extensive Stage Small Cell Lung Carcinoma

08/24

10/24

Recruiting

1/2

74

 

HTMC0435 tablets 8 mg, bid, continued daily oral administration, each dose group combined with etoposide 75 mg/m^2, intravenous infusion for about 60 minutes, for 3 days (day 1 to day 3 of each treatment cycle), combined with cisplatin 20mg/m^2 (intravenous infusion > 1h), for a total of 3 days (days 1 to 3 of each treatment cycle) or carboplatin AUC4 (intravenous infusion for 30-60min), a total of 1 day (day 1 of each treatment cycle), 21 days per treatment cycle, A total of 4-6 cycles of treatment. In principle, the subsequent escalation dose was increased in the ratio of ×1.33 (33%).; HTMC0435 tablets 12 mg, bid, continuous oral administration every day, each dose group combined with etoposide 75 mg/m^2, intravenous infusion for about 60 minutes, for 3 days (day 1 to day 3 of each treatment cycle), combined with cisplatin 20mg/m^2 (intravenous infusion > 1h), for a total of 3 days (days 1 to 3 of each treatment cycle) or carboplatin AUC4 (intravenous infusion for 30-60min), a total of 1 day (day 1 of each treatment cycle), each treatment cycle of 21 days for a total of 4-6 cycles of treatment. In principle, the subsequent escalation dose was increased in the ratio of ×1.33 (33%).; The preliminary efficacy of the combination in patients with extensive-stage small cell lung cancer was investigated at the dose of HTMC0435 tablets in combination with cisplatin/carboplatin and etoposide RP2D. Subjects who have no progression after 4-6 cycles of treatment and are tolerated after investigator safety assessment will continue to be treated with HTMC0435 single-agent RP2D dose maintenance therapy.

The First Affiliated Hospital of Zhengzhou University; Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Small Cell Lung Cancer

 

 

Recruiting

N/A

10000

US

Loxapine 10 MG, ADASUVE (loxapine) inhalation powder, NDA 022549

Alexza Pharmaceuticals, Inc., Pharmaceutical Research Associates

Agitation,Psychomotor

10/21

03/22

Active, not recruiting

1

13

US

Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Birinapant, TL32711, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

National Cancer Institute (NCI)

Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma

11/23

03/26

1/2

53

Europe, RoW

MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib

Medivir

Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases

01/25